These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Cardiorespiratory safety evaluation in non-human primates. Ingram-Ross JL; Curran AK; Miyamoto M; Sheehan J; Thomas G; Verbeeck J; de Waal EJ; Verstynen B; Pugsley MK J Pharmacol Toxicol Methods; 2012 Sep; 66(2):114-24. PubMed ID: 22521338 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report. Klein SK; Redfern WS J Pharmacol Toxicol Methods; 2015; 76():1-6. PubMed ID: 26126834 [TBL] [Abstract][Full Text] [Related]
29. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349 [TBL] [Abstract][Full Text] [Related]
30. Twenty years of safety pharmacology model validation and the wider implications of this to drug discovery. Pugsley MK; Bekele B; Griessel H; de Korte T; Authier S; Grobler AF; Markgraf CG; Curtis MJ J Pharmacol Toxicol Methods; 2020 Sep; 105():106912. PubMed ID: 32798702 [TBL] [Abstract][Full Text] [Related]
31. The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. Ewart L; Aylott M; Deurinck M; Engwall M; Gallacher DJ; Geys H; Jarvis P; Ju H; Leishman D; Leong L; McMahon N; Mead A; Milliken P; Suter W; Teisman A; Van Ammel K; Vargas HM; Wallis R; Valentin JP Toxicol Sci; 2014 Dec; 142(2):427-35. PubMed ID: 25246669 [TBL] [Abstract][Full Text] [Related]
32. Drug development and nonclinical to clinical translational databases: past and current efforts. Monticello TM Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276 [TBL] [Abstract][Full Text] [Related]
33. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
35. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566 [TBL] [Abstract][Full Text] [Related]
36. The shifting landscape of safety pharmacology in 2015. Pugsley MK; Authier S; Stonerook M; Curtis MJ J Pharmacol Toxicol Methods; 2015; 75():5-9. PubMed ID: 26055120 [TBL] [Abstract][Full Text] [Related]
37. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making. Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186 [TBL] [Abstract][Full Text] [Related]
38. Conscious sedation guidance. Coulthard P Evid Based Dent; 2006; 7(4):90-1. PubMed ID: 17187034 [TBL] [Abstract][Full Text] [Related]